Immunocore Holdings plc (NASDAQ:IMCR) Shares Purchased by The Manufacturers Life Insurance Company

The Manufacturers Life Insurance Company increased its position in shares of Immunocore Holdings plc (NASDAQ:IMCR) by 37.2% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 121,753 shares of the company’s stock after acquiring an additional 33,003 shares during the period. The Manufacturers Life Insurance Company owned about 0.24% of Immunocore worth $4,126,000 at the end of the most recent quarter.

Other hedge funds have also recently bought and sold shares of the company. DNB Asset Management AS lifted its stake in Immunocore by 35.0% during the 2nd quarter. DNB Asset Management AS now owns 7,211 shares of the company’s stock worth $244,000 after acquiring an additional 1,868 shares in the last quarter. XTX Topco Ltd acquired a new position in Immunocore during the 2nd quarter worth about $303,000. Tidal Investments LLC acquired a new position in Immunocore during the 1st quarter worth about $423,000. China Universal Asset Management Co. Ltd. increased its holdings in Immunocore by 69.8% during the 1st quarter. China Universal Asset Management Co. Ltd. now owns 6,621 shares of the company’s stock worth $430,000 after purchasing an additional 2,721 shares during the period. Finally, Seven Eight Capital LP purchased a new stake in Immunocore during the 2nd quarter worth about $434,000. Institutional investors and hedge funds own 84.50% of the company’s stock.

Analyst Ratings Changes

IMCR has been the topic of several recent research reports. Cantor Fitzgerald restated an “overweight” rating on shares of Immunocore in a report on Monday, September 9th. Needham & Company LLC cut their price target on Immunocore from $81.00 to $78.00 and set a “buy” rating on the stock in a report on Tuesday, September 17th. HC Wainwright restated a “buy” rating and set a $100.00 price target on shares of Immunocore in a report on Tuesday, September 17th. Oppenheimer restated an “outperform” rating and set a $89.00 price target (up previously from $87.00) on shares of Immunocore in a report on Friday, August 9th. Finally, Barclays cut their price target on Immunocore from $92.00 to $66.00 and set an “overweight” rating on the stock in a report on Friday, August 9th. Two research analysts have rated the stock with a hold rating and ten have given a buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $80.40.

Immunocore Stock Down 1.2 %

Shares of NASDAQ IMCR opened at $30.75 on Tuesday. The stock has a market cap of $1.54 billion, a PE ratio of -25.20 and a beta of 0.72. The company has a quick ratio of 5.15, a current ratio of 5.17 and a debt-to-equity ratio of 1.31. Immunocore Holdings plc has a 52-week low of $29.72 and a 52-week high of $76.98. The business has a 50-day moving average price of $35.07 and a 200 day moving average price of $44.10.

Immunocore (NASDAQ:IMCR) last announced its earnings results on Thursday, August 8th. The company reported ($0.23) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.48) by $0.25. The firm had revenue of $75.40 million during the quarter, compared to analysts’ expectations of $74.58 million. Immunocore had a negative return on equity of 14.68% and a negative net margin of 19.16%. The business’s revenue was up 26.2% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.37) EPS. Equities research analysts forecast that Immunocore Holdings plc will post -1.79 earnings per share for the current year.

Immunocore Company Profile

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.